Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
23 Setembro 2024 - 1:56PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2024
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
99.1
|
23
September 2024 - “Transaction in Own
Shares”
|
99.1
Haleon plc: Transaction in own shares
23 September 2024: Haleon plc (the “Company” or
“Haleon”) today announces the purchase of the following
number of ordinary shares of £0.01 each in the Company (the
“Shares”) for cancellation under its share buyback
programme announced on 1 August 2024 (the “Buyback
Programme”).
|
|
23
September 2024
|
|
Number
of Shares purchased:
|
506,899
|
|
Highest
price paid per Share (p):
|
395.5000
|
|
Lowest
price paid per Share (p):
|
389.1000
|
|
Volume
weighted average price paid per Share (p):
|
392.9671
|
Following
the settlement of the above, the Company's registered share capital
consists of 9,115,151,424 ordinary shares. This figure may be used
by shareholders to determine if they are required to notify their
interest, or a change to their interest, in Haleon under the FCA's
Disclosure Guidance and Transparency Rules.
In
accordance with Article 5s(1)(b) of Regulation (EU) No 596/2014 as
it applies in the UK (the Market Abuse Regulation), a
full breakdown of the individual trades is available at the link
below:
http://www.rns-pdf.londonstockexchange.com/rns/3128F_1-2024-9-23.pdf
This
announcement does not constitute, or form part of, an offer or any
solicitation of an offer for securities in any
jurisdiction.
This
announcement and individual trade breakdown will also be available
on the Company's website at: www.haleon.com/investors.
|
Enquiries
|
|
|
Investors
|
Media
|
|
Sonya
Ghobrial
|
+44
7392 784784
|
Zoë
Bird
|
+44
7736 746167
|
|
Rakesh
Patel
|
+44
7552 484646
|
Gemma
Thomas
|
+44
7985 175048
|
|
Emma
White
|
+44
7823 523562
|
|
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health,
with a purpose to deliver better everyday health with humanity.
Haleon's product portfolio spans five major categories - Oral
Health, Pain Relief, Respiratory Health, Digestive Health and
Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren,
Theraflu, Otrivin, Polident, parodontax and Centrum - are built on
trusted science, innovation and deep human
understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
Date:
September 23, 2024
|
By:
|
/s/
Amanda Mellor
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|
Haleon (NYSE:HLN)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Haleon (NYSE:HLN)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
